MARCH GLADNESS is a certainty to me, friend, and after staying with this company for four years, I am more than ready for it.
And for me, there was significant progress this month. Even though we have still not broken out of the algorithm that pegs our share price to CYDY's share price, we are finally trading at more than 5 times the price of CYDY (which is to say that our share price is higher than theirs' on a pre-reverse split basis). That sub-CYDY price valuation has been a major burn in my backside, ever since we announced the reverse.
Durrant is on the threshold of launching his 7th blockbuster drug, one generating more than $1B in sales annually. And this after only one year of development! Incredible.
And thank goodness for Chappell's teflon sports coats! I'm sure that guy took more heat than any of us ever has by reacting quickly to a changing clinical environment, and modifying our endpoints to meet the evolving regulatory focus. That's something that RLFTF (NeuroRx) and CYDY chose not to do, and now that they failed to meet their primary endpoints, they are following Chappell's lead. It should be noted that HGEN was denigrated, and that the efficacy of lenz was disparaged by many after changing our endpoints once the trial had started. And now, we are likely poised to get an EUA from the FDA, and the Philippines/South Korea, as well as conditional approval of our Marketing Authorization Applications in the UK and Europe, which we will submit after topline data is released. That's the MARCH GLADNESS I'm looking forward to experiencing. And that's not even a full accounting of the world-wide acceptance of lenz, Brazil included, for example.
AI
